Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Sergey Karakashev; Rugang Zhang

doi:10.1080/23723556.2020.1760675

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors

Mol Cell Oncol. 2020 May 23;7(4):1760675. doi: 10.1080/23723556.2020.1760675. eCollection 2020.

Authors

Sergey Karakashev¹, Rugang Zhang¹

Affiliation

¹ Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

Keywords: coactivator-associated arginine methyltransferase 1 (CARM1); enhancer of zeste homology 2 (EZH2) inhibitors; epithelial ovarian cancer; homologous recombination (HR); immune checkpoint blockers; mitotic arrest deficient 2 like 2 (MAD2L2); non-homologous end-joining (NHEJ); poly (ADP-ribose) polymerase (PARP) inhibitors.

Abstract

Grants and funding